Acquisition – Page 2

Merck Q3 2025: Solid Organic Growth Across All Sectors

4 weeks ago talkbio0Tagged Acquisition, Animal Health, Gross margin, Keytruda, Merck, Neoplasms, new product, organic growth, Pharma, Q3 2025, Verona

Merck; Q3 2025; Organic growth; KEYTRUDA; Oncology; Animal Health; Verona Pharma acquisition; Gross margin; Revenue; New product launches

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

1 month ago talkbio0Tagged Acquisition, Approved, bidding war, Drug Industry, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, shareholder

Pfizer; Novo Nordisk; Metsera; obesity drugs; GLP-1; acquisition; bidding war; shareholder approval; pharmaceutical industry

Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers

1 month ago talkbio0Tagged Acquisition, Antitrust, bidding war, Disputes, Dominance, Glucagon-Like Peptide 1, Legal, Market, Metsera, Novo Nordisk, Obesity, Pfizer

Metsera; obesity drugs; bidding war; Novo Nordisk; Pfizer; acquisition; GLP-1; antitrust; market dominance; legal disputes

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

1 month ago talkbio0Tagged Acquisition, analysts, Antitrust, Buyout, CEO Mike, lawsuit, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; acquisition; Pfizer; buyout; obesity drugs; analysts; lawsuit; antitrust; CEO Mike Doustdar

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer

1 month ago talkbio0Tagged Acquisition, contingent value right, Diabetes, M&A, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

1 month ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Novartis CEO on $12B Avidity Deal: ‘Could Have Been Twice as Big’

2 months ago talkbio0Tagged Acquisition, Avidity Biosciences, financial outlook, growth strategy, Merger, Neuromuscular Diseases, Novartis, RNA, SpinCo ', Vas Narasimhan

Novartis; Avidity Biosciences; Vas Narasimhan; merger; acquisition; biotech; RNA therapeutics; $12 billion deal; neuromuscular diseases; SpinCo; financial outlook; growth strategy

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

2 months ago talkbio0Tagged 2026, Acquisition, AOC, Avidity Biosciences, Closed, Muscular Dystrophy, Duchenne, Muscular Dystrophy, Facioscapulohumeral, MYOTONIC DYSTROPHY 1, Neuromuscular Diseases, Novartis, Platform, RNA therapeutics, SpinCo ', xRNA

Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing

Lilly Expands Gene Therapy Presence with Acquisition of Adverum Biotechnologies

2 months ago talkbio0Tagged Acquisition, Adverum Biotechnologies, contingent value, eli lilly, gene therapy, ixovec, Ophthalmology specialty, Wet Age-Related Macular Degeneration

Eli Lilly; Adverum Biotechnologies; gene therapy; ophthalmology; wet age-related macular degeneration; ixovec; acquisition; contingent value rights

Alkermes Acquires Avadel Pharmaceuticals for $2.1B, Gaining Sleep Drug LUMRYZ and Setting Strategic Evolution

2 months ago talkbio0Tagged Acquisition, Alkermes, Avadel Pharmaceuticals, Biological Factors, LUMRYZ, Narcolepsy, portfolio, premium, Rare Diseases, Sleep medicine specialist, strategic

Alkermes; Avadel Pharmaceuticals; acquisition; LUMRYZ; narcolepsy; sleep medicine; strategic portfolio; biopharmaceuticals; rare disease; deal premium